KF
Insider
Kevin Joseph Fitzgerald
CSO & EVP, Head of ResearchKevin Joseph Fitzgerald (CSO & EVP, Head of Research) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Alnylam Pharmaceuticals, Inc. (ALNY). The largest single filing was $5.4M of ALNY (11,903 sh across 9 lots, as filed), executed Nov 17 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.7M
shares × price, as filed
Last traded
Mar 3
Filed Mar 4
Median ADV $470.9M across their filed names
Open performance→Volume by month
Buys $0
Sells $10.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
ALNYRecent filings
ALNYSALE
Alnylam Pharmaceuticals, Inc.
View filing →
$583K1,802 sh across 4 lots
Exec Mar 2
Filed Mar 4 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $1.3M
4,000 sh across 2 lots
Exec Feb 13
Filed Feb 17 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $730K
1,971 sh across 4 lots
Exec Jan 13
Filed Jan 14 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $5.4M
11,903 sh across 9 lots
Exec Nov 17 2025
Filed Nov 19 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $702K
1,553 sh across 4 lots
Exec Oct 2 2025
Filed Oct 3 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $505K
1,113 sh across 3 lots
Exec Aug 18 2025
Filed Aug 19 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $232K
952 sh across 2 lots
Exec Mar 3 2025
Filed Mar 5 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $272K
1,086 sh × $250.21
Exec Feb 18 2025
Filed Feb 18 2025 · 5:30 PM ET More filings →